Last reviewed · How we verify

Spot ALA 2 hour incubation

DUSA Pharmaceuticals, Inc. · Phase 2 active Small molecule

Spot ALA 2 hour incubation is a Small molecule drug developed by DUSA Pharmaceuticals, Inc.. It is currently in Phase 2 development. Also known as: Levulan.

At a glance

Generic nameSpot ALA 2 hour incubation
Also known asLevulan
SponsorDUSA Pharmaceuticals, Inc.
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Spot ALA 2 hour incubation

What is Spot ALA 2 hour incubation?

Spot ALA 2 hour incubation is a Small molecule drug developed by DUSA Pharmaceuticals, Inc..

Who makes Spot ALA 2 hour incubation?

Spot ALA 2 hour incubation is developed by DUSA Pharmaceuticals, Inc. (see full DUSA Pharmaceuticals, Inc. pipeline at /company/dusa-pharmaceuticals-inc).

Is Spot ALA 2 hour incubation also known as anything else?

Spot ALA 2 hour incubation is also known as Levulan.

What development phase is Spot ALA 2 hour incubation in?

Spot ALA 2 hour incubation is in Phase 2.

Related